Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab

Patients with Crohn ’s disease (CD) or ulcerative colitis (UC) often receive combination therapy with an immunomodulator and tumor necrosis factor antagonists, especially infliximab. However, the benefits of combination therapy with vedolizumab and ustekinumab are unclear.

Source: Clinical Gastroenterology and Hepatology - July 10, 2020 Category: Gastroenterology Authors: Anne Hu, Paulo Gustavo Kotze, Alice Burgevin, Willam Tan, Alison Jess, Pei-Shun Li, Karen Kroeker, Brendan Halloran, Remo Panaccione, Laurent Peyrin-Biroulet, Christopher Ma, Ashwin N. Ananthakrishnan Source Type: research